Women’s Special Issue Series: Biomedicines

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 53837

Special Issue Editors


E-Mail Website
Guest Editor
Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy
Interests: cancer therapy; drug delivery; immunoconjugates; immune targeting; plant toxins
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to announce a Special Issue entitled “Women’s Special Issue Series: Biomedicines” to celebrate and highlight the achievements of women in the development of new molecules and therapies for cancer research area.

For this Special Issue, we are seeking the submission of original research articles and comprehensive review papers from oncology-related fields, in particular regarding new therapeutic targets, therapeutic strategies, and research of biomedicines and biopharmaceutical products.

The Series advocates the advancement of women in science. We invite contributions to the Special Issue whose lead authors identify as women. The submission of articles with all-women authorship is especially encouraged. However, we do welcome articles from all authors, irrespective of gender.

Dr. Letizia Polito
Dr. Nadia Alfaidy
Guest Editors

Women’s Special Issue Series

This Special Issue is part of Biomedicines's Women’s Special Issue Series, hosted by women editors for women researchers. The Series advocates the advancement of women in science. We invite contributions to the Special Issue whose lead authors identify as women. The submission of articles with all-women authorship is especially encouraged. However, we do welcome articles from all authors, irrespective of gender.

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibody
  • biomedicines
  • biopharmaceutical products
  • cancer therapy
  • drug delivery
  • immunoconjugates
  • immunotoxins
  • immunotherapy
  • immunotargeting
  • nanodelivery
  • toxin

Published Papers (10 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review, Other

4 pages, 181 KiB  
Editorial
Women’s Special Issue Series: Biomedicines
by Letizia Polito
Biomedicines 2024, 12(3), 471; https://doi.org/10.3390/biomedicines12030471 - 20 Feb 2024
Viewed by 487
Abstract
Following the invitation of Biomedicines, we decided to accept the project of this Special Issue because we believe that in many situations gender prejudices still exist and put women in a disadvantaged position for the dissemination of their research, preventing the scientific [...] Read more.
Following the invitation of Biomedicines, we decided to accept the project of this Special Issue because we believe that in many situations gender prejudices still exist and put women in a disadvantaged position for the dissemination of their research, preventing the scientific community from benefiting from a plurality of voices in the interpretation of scientific research [...] Full article
(This article belongs to the Special Issue Women’s Special Issue Series: Biomedicines)

Research

Jump to: Editorial, Review, Other

10 pages, 492 KiB  
Article
Clinical Implication of PD-L1 Expression in Patients with Endometrial Cancer
by Yeorae Kim, Ala Aiob, Hyojin Kim, Dong Hoon Suh, Kidong Kim, Yong Beom Kim and Jae Hong No
Biomedicines 2023, 11(10), 2691; https://doi.org/10.3390/biomedicines11102691 - 01 Oct 2023
Cited by 1 | Viewed by 1072
Abstract
This study investigated PD-L1 expression in endometrial cancer, its links with prognostic factors, and survival outcomes in 232 patients. Of these, 73 (31.5%) had PD-L1-positive tumors and 159 (68.5%) had PD-L1-negative tumors. PD-L1 expression significantly correlated with adverse prognostic factors. The PD-L1-positive group [...] Read more.
This study investigated PD-L1 expression in endometrial cancer, its links with prognostic factors, and survival outcomes in 232 patients. Of these, 73 (31.5%) had PD-L1-positive tumors and 159 (68.5%) had PD-L1-negative tumors. PD-L1 expression significantly correlated with adverse prognostic factors. The PD-L1-positive group had higher rates of high-grade tumors (37.0% vs. 19.1%, p = 0.004), deep myometrial invasion (35.6% vs. 24.4%, p = 0.004), lymphovascular space invasion (LVSI) (39.7% vs. 25.6%, p = 0.023), and lymph node metastasis (7.2% vs. 17.1%, p = 0.024) than the PD-L1-negative group. While 5-year progression-free survival (PFS) favored the PD-L1-negative group (94.1% vs. 86.3%), this difference lacked statistical significance (p = 0.139). No significant variations emerged in overall survival (OS) (p = 0.596) or recurrence rates between the groups. Although outcomes lack statistical significance, they suggest a plausible link between PD-L1 and established adverse prognostic factors, such as histological grade, myometrial invasion depth, LVSI, and lymph node metastasis in endometrial cancer. These insights hint at PD-L1’s potential as an informal prognostic indicator, potentially aiding in endometrial cancer patient management. Full article
(This article belongs to the Special Issue Women’s Special Issue Series: Biomedicines)
Show Figures

Figure 1

20 pages, 4442 KiB  
Article
Evaluation of Single Dose and Fractionated Dose of I-131 Radiolabeled Nanoparticles for Triple-Negative Breast Cancer Treatment
by Suphalak Khamruang Marshall, Nutnicha Kaewpradit, Tavadee Mudmarn, Jirassaya Buathong and Palmuk Sriwirote
Biomedicines 2023, 11(8), 2169; https://doi.org/10.3390/biomedicines11082169 - 01 Aug 2023
Cited by 2 | Viewed by 35837
Abstract
Combination chemotherapy is still the standard clinical care for triple-negative breast cancer (TNBC). However, sodium iodide symporter (NIS) uptake by TNBC has opened the potential of NIS as a molecular target for radioiodine theranostic treatments. Radiolabeled poly(lactic-co-glycolic) acid nanocarrier (NINP) was developed for [...] Read more.
Combination chemotherapy is still the standard clinical care for triple-negative breast cancer (TNBC). However, sodium iodide symporter (NIS) uptake by TNBC has opened the potential of NIS as a molecular target for radioiodine theranostic treatments. Radiolabeled poly(lactic-co-glycolic) acid nanocarrier (NINP) was developed for NIS targeted delivery of I-131 to MDA-MB-231 cells to overcome I-131 low uptake in cancer cells and rapid clearance. The NINP diameter of 237 nm has good particle size uniformity and excellent particle stability. Radiochemical purity, radioactive stability, and radiolabeling yield of NINPs over 72 h were >95%. Cytotoxicity confirmed fractionated NINPs over 72 h to be more effective in cell death than single-dose NINP and both single and fractionated Na131I. Cellular uptake in a three-dimensional spheroid confirmed that NINP fractionated-dose achieved ~4.8-fold-higher mean fluorescent intensity than Na131I and ~2.7-fold greater reduction in cell viability compared to single-dose. The NINP fractionated-dose initiated greater cellular DNA damage to cells than single-dose NINP, resulting in inhibition of cell cycle progression, resulting in cell cycle progression being inhibited by cyclin-dependent kinases, which play a vital role in the control of MDA-MB-231 cell cycle. NINPs are biocompatible with blood, and were found to have no negative impact on red blood cells. Full article
(This article belongs to the Special Issue Women’s Special Issue Series: Biomedicines)
Show Figures

Figure 1

14 pages, 4842 KiB  
Article
New Insights on Saporin Resistance to Chemical Derivatization with Heterobifunctional Reagents
by Massimo Bortolotti, Francesco Biscotti, Andrea Zanello, Andrea Bolognesi and Letizia Polito
Biomedicines 2023, 11(4), 1214; https://doi.org/10.3390/biomedicines11041214 - 19 Apr 2023
Cited by 2 | Viewed by 1580
Abstract
Saporin is a type 1 ribosome-inactivating protein widely used as toxic payload in the construction of targeted toxins, chimeric molecules formed by a toxic portion linked to a carrier moiety. Among the most used carriers, there are large molecules (mainly antibodies) and small [...] Read more.
Saporin is a type 1 ribosome-inactivating protein widely used as toxic payload in the construction of targeted toxins, chimeric molecules formed by a toxic portion linked to a carrier moiety. Among the most used carriers, there are large molecules (mainly antibodies) and small molecules (such as neurotransmitters, growth factors and peptides). Some saporin-containing targeted toxins have been used for the experimental treatment of several diseases, giving very promising results. In this context, one of the reasons for the successful use of saporin lies in its resistance to proteolytic enzymes and to conjugation procedures. In this paper, we evaluated the influence of derivatization on saporin using three heterobifunctional reagents, namely 2-iminothiolane (2-IT), N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP) and 4-succinimidyloxycarbonyl-α-methyl-α-[2-pyridyldithio]toluene (SMPT). In order to obtain the highest number of inserted -SH groups with the lowest reduction of saporin biological activities, we assessed the residual ability of saporin to inhibit protein synthesis, to depurinate DNA and to induce cytotoxicity after derivatization. Our results demonstrate that saporin maintains an excellent resistance to derivatization processes, especially with SPDP, and permit us to define reaction conditions, in which saporin biological properties may not be altered. Therefore, these findings provide useful information for the construction of saporin-based targeted toxins, especially with small carriers. Full article
(This article belongs to the Special Issue Women’s Special Issue Series: Biomedicines)
Show Figures

Figure 1

12 pages, 5135 KiB  
Article
Urolithin A’s Antioxidative, Anti-Inflammatory, and Antiapoptotic Activities Mitigate Doxorubicin-Induced Liver Injury in Wistar Rats
by Shahid Karim, Batoul Madani, Abdulhadi S. Burzangi, Mohammed Alsieni, Mohammed A. Bazuhair, Maha Jamal, Hussam Daghistani, Mohammed O. Barasheed, Huda Alkreathy, Mohammad Ahmed Khan and Lateef M. Khan
Biomedicines 2023, 11(4), 1125; https://doi.org/10.3390/biomedicines11041125 - 07 Apr 2023
Cited by 6 | Viewed by 2275
Abstract
Human colon microbiota produce a metabolite called urolithin A (URO A) from ellagic acid and linked compounds, and this metabolite has been demonstrated to have antioxidant, anti-inflammatory, and antiapoptotic activities. The current work examines the various mechanisms through which URO A protects against [...] Read more.
Human colon microbiota produce a metabolite called urolithin A (URO A) from ellagic acid and linked compounds, and this metabolite has been demonstrated to have antioxidant, anti-inflammatory, and antiapoptotic activities. The current work examines the various mechanisms through which URO A protects against doxorubicin (DOX)-induced liver injury in Wistar rats. In this experiment, Wistar rats were administered DOX intraperitoneally (20 mg kg−1) on day 7 while given URO A intraperitoneally (2.5 or 5 mg kg−1 d−1) for 14 days. The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma glutamyl transferase (GGT) were measured. Hematoxylin and eosin (HE) staining was used to evaluate histopathological characteristics, and then antioxidant and anti-inflammatory properties were evaluated in tissue and serum, respectively. We also looked at how active caspase 3 and cytochrome c oxidase were in the liver. The findings demonstrated that supplementary URO A therapy clearly mitigated DOX-induced liver damage. The antioxidant enzymes SOD and CAT were elevated in the liver, and the levels of inflammatory cytokines, such as TNF-α, NF-kB, and IL-6, in the tissue were significantly attenuated, all of which complemented the beneficial effects of URO A in DOX-induced liver injury. In addition, URO A was able to alter the expression of caspase 3 and cytochrome c oxidase in the livers of rats that were subjected to DOX stress. These results showed that URO A reduced DOX-induced liver injury by reducing oxidative stress, inflammation, and apoptosis. Full article
(This article belongs to the Special Issue Women’s Special Issue Series: Biomedicines)
Show Figures

Figure 1

14 pages, 5758 KiB  
Article
Biochemical, Histological, and Ultrastructural Studies of the Protective Role of Vitamin E on Cyclophosphamide-Induced Cardiotoxicity in Male Rats
by Azza A. Attia, Jehan M. Sorour, Neama A. Mohamed, Tagreed T. Mansour, Rasha A. Al-Eisa and Nahla S. El-Shenawy
Biomedicines 2023, 11(2), 390; https://doi.org/10.3390/biomedicines11020390 - 28 Jan 2023
Cited by 5 | Viewed by 2025
Abstract
Background: Cyclophosphamide (CP) (Cytoxan or Endoxan) is an efficient anti-tumor agent, widely used for the treatment of various neoplastic diseases. The study aimed to investigate the protective role of vitamin E (vit E) in improving cardiotoxicity in rats induced by CP. Materials and [...] Read more.
Background: Cyclophosphamide (CP) (Cytoxan or Endoxan) is an efficient anti-tumor agent, widely used for the treatment of various neoplastic diseases. The study aimed to investigate the protective role of vitamin E (vit E) in improving cardiotoxicity in rats induced by CP. Materials and methods: Forty male Wistar rats were divided randomly into four experimental groups (each consisting of ten rats); the control group was treated with saline. The other three groups were treated with vit E, CP, and the combination of vit E and CP. Serum lipid profiles, enzyme cardiac biomarkers, and cardiac tissue antioxidants were evaluated, as well as histological and ultrastructure investigations. Results: CP-treated rats showed a significant increase in serum levels of cardiac markers (troponin, CK, LDH, AST, and ALT), lipid profiles, a reduction in the antioxidant enzyme activities (CAT, SOD, and GPx), and an elevation in the level of lipid peroxidation (LPO). The increase in the levels of troponin, LDH, AST, ALP, and triglycerides is a predominant indicator of cardiac damage due to the toxic effect of CP. The biochemical changes parallel cardiac injuries such as myocardial infarction, myocarditis, and heart failure. Vitamin E played a pivotal role, as it attenuated most of these changes because of its ability to scavenge free radicals and reduce LPO. In addition, vit E was found to improve the histopathological alterations caused by CP where no evidence of damage was observed in the cardiac architecture, and the cardiac fibers had regained their normal structure with minimal hemorrhage. Conclusions: As a result of its antioxidant activity and its stabilizing impact on the cardiomyocyte membranes, vit E is recommended as a potential candidate in decreasing the damaging effects of CP. Full article
(This article belongs to the Special Issue Women’s Special Issue Series: Biomedicines)
Show Figures

Figure 1

11 pages, 1987 KiB  
Article
Lower Extremity Arterial Disease in Type 2 Diabetes Mellitus: Metformin Inhibits Femoral Artery Ultrastructural Alterations as well as Vascular Tissue Levels of AGEs/ET-1 Axis-Mediated Inflammation and Modulation of Vascular iNOS and eNOS Expression
by Ayed A. Shati, Amro Maarouf, Amal F. Dawood, Nervana M. Bayoumy, Youssef A. Alqahtani, Refaat A. Eid, Saeed M. Alqahtani, Mohamed Abd Ellatif, Bahjat Al-Ani and Alia Albawardi
Biomedicines 2023, 11(2), 361; https://doi.org/10.3390/biomedicines11020361 - 26 Jan 2023
Cited by 2 | Viewed by 1613
Abstract
Lower extremity arterial disease (LEAD) is a major risk factor for amputation in diabetic patients. The advanced glycation end products (AGEs)/endothelin-1 (ET-1)/nitric oxide synthase (NOS) axis-mediated femoral artery injury with and without metformin has not been previously investigated. Type 2 diabetes mellitus (T2DM) [...] Read more.
Lower extremity arterial disease (LEAD) is a major risk factor for amputation in diabetic patients. The advanced glycation end products (AGEs)/endothelin-1 (ET-1)/nitric oxide synthase (NOS) axis-mediated femoral artery injury with and without metformin has not been previously investigated. Type 2 diabetes mellitus (T2DM) was established in rats, with another group of rats treated for two weeks with 200 mg/kg metformin, before being induced with T2DM. The latter cohort were continued on metformin until they were sacrificed at week 12. Femoral artery injury was established in the diabetic group as demonstrated by substantial alterations to the femoral artery ultrastructure, which importantly were ameliorated by metformin. In addition, diabetes caused a significant (p < 0.0001) upregulation of vascular tissue levels of AGEs, ET-1, and iNOS, as well as high blood levels of glycated haemoglobin, TNF-α, and dyslipidemia. All of these parameters were also significantly inhibited by metformin. Moreover, metformin treatment augmented arterial eNOS expression which had been inhibited by diabetes progression. Furthermore, a significant correlation was observed between femoral artery endothelial tissue damage and glycemia, AGEs, ET-1, TNF-α, and dyslipidemia. Thus, in a rat model of T2DM-induced LEAD, an association between femoral artery tissue damage and the AGEs/ET-1/inflammation/NOS/dyslipidemia axis was demonstrated, with metformin treatment demonstrating beneficial vascular protective effects. Full article
(This article belongs to the Special Issue Women’s Special Issue Series: Biomedicines)
Show Figures

Figure 1

14 pages, 2568 KiB  
Article
Epithelial Cell Adhesion Molecule (EpCAM) Expression Can Be Modulated via NFκB
by Saadiya Zia, Komal Tehreem, Sidra Batool, Mehreen Ishfaq, Shaher Bano Mirza, Shahrukh Khan, Majed N. Almashjary, Mohannad S. Hazzazi, Husam Qanash, Ahmad Shaikh, Roua S. Baty, Ibrahim Jafri, Nouf H. Alsubhi, Ghadeer I. Alrefaei, Rokayya Sami and Ramla Shahid
Biomedicines 2022, 10(11), 2985; https://doi.org/10.3390/biomedicines10112985 - 20 Nov 2022
Cited by 3 | Viewed by 2361
Abstract
The epithelial cell adhesion molecule (EpCAM) is considered an essential proliferation signature in cancer. In the current research study, qPCR induced expression of EpCAM was noted in acute lymphoblastic leukemia (ALL) cases. Costunolide, a sesquiterpene lactone found in crepe ginger and lettuce, is [...] Read more.
The epithelial cell adhesion molecule (EpCAM) is considered an essential proliferation signature in cancer. In the current research study, qPCR induced expression of EpCAM was noted in acute lymphoblastic leukemia (ALL) cases. Costunolide, a sesquiterpene lactone found in crepe ginger and lettuce, is a medicinal herb with anticancer properties. Expression of EpCAM and its downstream target genes (Myc and TERT) wasdownregulated upon treatment with costunolide in Jurkat cells. A significant change in the telomere length of Jurkat cells was not noted at 72 h of costunolide treatment. An in silico study revealed hydrophobic interactions between EpCAM extracellular domain and Myc bHLH with costunolide. Reduced expression of NFκB, a transcription factor of EpCAM, Myc, and TERT in costunolide-treated Jurkat cells, suggested that costunolide inhibits gene expression by targeting NFκB and its downstream targets. Overall, the study proposes that costunolide could be a promising therapeutic biomolecule for leukemia. Full article
(This article belongs to the Special Issue Women’s Special Issue Series: Biomedicines)
Show Figures

Figure 1

Review

Jump to: Editorial, Research, Other

18 pages, 1527 KiB  
Review
Oncogenic Long Noncoding RNAs in Prostate Cancer, Osteosarcoma, and Metastasis
by Aishah Al-Shehri and Sherin Bakhashab
Biomedicines 2023, 11(2), 633; https://doi.org/10.3390/biomedicines11020633 - 20 Feb 2023
Cited by 1 | Viewed by 1867
Abstract
Prostate cancer (PC) is a common malignancy and is one of the leading causes of cancer-related death in men worldwide. Osteosarcoma (OS) is the most common bone cancer, representing 20–40% of all bone malignancy cases. Cancer metastasis is a process by which malignant [...] Read more.
Prostate cancer (PC) is a common malignancy and is one of the leading causes of cancer-related death in men worldwide. Osteosarcoma (OS) is the most common bone cancer, representing 20–40% of all bone malignancy cases. Cancer metastasis is a process by which malignant tumor cells detach from the primary tumor site via a cascade of processes and migrate to secondary sites through the blood circulation or lymphatic system to colonize and form secondary tumors. PC has a specific affinity to the bone based on the “seed and soil” theory; once PC reach the bone, it becomes incurable. Several studies have identified long noncoding RNAs (lncRNAs) as potential targets for cancer therapy or as diagnostic and prognostic biomarkers. The dysregulation of various lncRNAs has been found in various cancer types, including PC, OS, and metastasis. However, the mechanisms underlying lncRNA oncogenic activity in tumor progression and metastasis are extremely complex and remain incompletely understood. Therefore, understanding oncogenic lncRNAs and their role in OS, PC, and metastasis and the underlying mechanism may help better manage and treat this malignancy. The aim of this review is to summarize current knowledge of oncogenic lncRNAs and their involvement in PC, OS, and bone metastasis. Full article
(This article belongs to the Special Issue Women’s Special Issue Series: Biomedicines)
Show Figures

Figure 1

Other

11 pages, 674 KiB  
Systematic Review
Lactated Ringer’s Solution Reduces Severity, Mortality, Systemic and Local Complications in Acute Pancreatitis: A Systematic Review and Meta-Analysis
by Klementina Ocskay, Péter Mátrai, Péter Hegyi and Andrea Párniczky
Biomedicines 2023, 11(2), 321; https://doi.org/10.3390/biomedicines11020321 - 23 Jan 2023
Cited by 4 | Viewed by 2430
Abstract
Fluid therapy is the cornerstone of early supportive therapy in acute pancreatitis (AP). Regrettably, the type of fluid is still debated among clinicians, despite recent evidence from randomized controlled trials (RCTs). We aimed to incorporate all evidence from RCTs comparing lactated Ringer’s solution [...] Read more.
Fluid therapy is the cornerstone of early supportive therapy in acute pancreatitis (AP). Regrettably, the type of fluid is still debated among clinicians, despite recent evidence from randomized controlled trials (RCTs). We aimed to incorporate all evidence from RCTs comparing lactated Ringer’s solution (LR) with normal saline (NS) in adult and pediatric AP patients, with particular emphasis on clinically relevant outcomes. We evaluated RCTs comparing intravenous fluid resuscitation with LR to NS in adult or pediatric AP patients according to a prospectively registered protocol (CRD42021224542). Moderate-to-severe AP (MSAP), mortality, length of hospitalization (LoH), need for intensive care, the incidence of systemic (organ failure, OF) and local complications (in total), necrosis and pseudocyst formation were analyzed separately. Risk ratio (RR) and median difference (MD) were calculated with 95% confidence intervals (CI) using a random effect model. Risk of bias and quality of evidence were assessed. Altogether, 8 eligible RCTs were found, including 557 patients (LR: 278; NS: 279). LR reduced the risk of MSAP by 31% (RR: 0.59, 95% CI: 0.36–0.97, high quality) and the risk of death by 62% (RR: 0.48; 95% CI: 0.24–0.98, very low quality). LR was associated with a significantly lower risk of need for intensive care (RR: 0.50, 95% CI: 0.33–0.77), OF (RR: 0.78, 95% CI: 0.61–0.99) and local complications (RR: 0.64, 95% CI: 0.46–0.89). No significant risk reduction was observed for LoH (MD: −0.57 days, CI: −1.33–0.19), necrosis, pseudocyst and inflammatory parameters by LR compared to NS. LR reduces severity, mortality, need of intensive care and systemic and local complications in AP. Full article
(This article belongs to the Special Issue Women’s Special Issue Series: Biomedicines)
Show Figures

Figure 1

Back to TopTop